Literature DB >> 24454606

Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.

Oussama El Yazami Adli1, Jacques Corcos1.   

Abstract

Multiple sclerosis (MS) is the most common neuroinflammatory disease of the central nervous system and a leading cause of disability in young adults. Symptoms related to vesicourethral dysfunction are very prevalent, but not specific to underlying urodynamic abnormalities. Detrusor overactivity and detrusor external sphincter dysynergia are the most frequent findings and are usually linked. Botulinum neurotoxin-A injection represents a significant advance in the management of voiding dysfunction among MS patients failing first-line therapy. It significantly improves patients' urodynamic parameters and quality of life, with efficacy sustained by repeated injections and minimal risk of adverse events.

Entities:  

Year:  2014        PMID: 24454606      PMCID: PMC3896564          DOI: 10.5489/cuaj.1824

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  76 in total

1.  Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.

Authors:  Antonella Giannantoni; Savino M Di Stasi; Robert L Stephen; Vittorio Bini; Elisabetta Costantini; Massimo Porena
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

2.  Which preparation of botulinum toxin a should be used, where should it be injected, and how should its efficacy be assessed?

Authors:  Christopher R Chapple
Journal:  Eur Urol       Date:  2011-12-13       Impact factor: 20.096

3.  Lower urinary tract dysfunction in multiple sclerosis.

Authors:  M E Mayo; M P Chetner
Journal:  Urology       Date:  1992-01       Impact factor: 2.649

4.  Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity.

Authors:  Cristiano M Gomes; Jose E de Castro Filho; Ronald F Rejowski; Flavio E Trigo-Rocha; Homero Bruschini; Tarcisio E P de Barros Filho; Miguel Srougi
Journal:  Int Braz J Urol       Date:  2010 Jan-Feb       Impact factor: 1.541

5.  Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry.

Authors:  S T Mahajan; P B Patel; R A Marrie
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

6.  Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.

Authors:  Gilles Karsenty; Ehab Elzayat; Thomas Delapparent; Benoît St-Denis; Marie-Claude Lemieux; Jacques Corcos
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

Review 7.  Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects.

Authors:  Roderick MacDonald; Manoj Monga; Howard A Fink; Timothy J Wilt
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

Review 8.  A UK consensus on the management of the bladder in multiple sclerosis.

Authors:  C J Fowler; J N Panicker; M Drake; C Harris; S C W Harrison; M Kirby; M Lucas; N Macleod; J Mangnall; A North; B Porter; S Reid; N Russell; K Watkiss; M Wells
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-05       Impact factor: 10.154

9.  Relationship between neurological and urological status in patients with multiple sclerosis.

Authors:  S A Awad; J B Gajewski; S K Sogbein; T J Murray; C A Field
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

10.  Botulinum injections for the treatment of bladder symptoms of multiple sclerosis.

Authors:  Vinay Kalsi; Gwen Gonzales; Roshni Popat; Apostolos Apostolidis; Sohier Elneil; Prokar Dasgupta; Clare J Fowler
Journal:  Ann Neurol       Date:  2007-11       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.